NO912825L - Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper. - Google Patents

Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.

Info

Publication number
NO912825L
NO912825L NO91912825A NO912825A NO912825L NO 912825 L NO912825 L NO 912825L NO 91912825 A NO91912825 A NO 91912825A NO 912825 A NO912825 A NO 912825A NO 912825 L NO912825 L NO 912825L
Authority
NO
Norway
Prior art keywords
munogent
protein
procedure
preparation
anionic groups
Prior art date
Application number
NO91912825A
Other languages
English (en)
Other versions
NO912825D0 (no
Inventor
William J Leanza
Stephen Marburg
Emilio A Emini
Richard L Tolman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO912825D0 publication Critical patent/NO912825D0/no
Publication of NO912825L publication Critical patent/NO912825L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO91912825A 1990-07-19 1991-07-18 Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper. NO912825L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55596690A 1990-07-19 1990-07-19
US55533990A 1990-07-19 1990-07-19
US71527891A 1991-06-19 1991-06-19
US71527691A 1991-06-19 1991-06-19

Publications (2)

Publication Number Publication Date
NO912825D0 NO912825D0 (no) 1991-07-18
NO912825L true NO912825L (no) 1992-01-20

Family

ID=27504782

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912825A NO912825L (no) 1990-07-19 1991-07-18 Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.

Country Status (11)

Country Link
US (1) US5606030A (no)
EP (1) EP0467700A3 (no)
JP (1) JPH07113038B2 (no)
KR (1) KR920002633A (no)
AU (1) AU8113591A (no)
CA (1) CA2047073A1 (no)
FI (1) FI913476A7 (no)
IE (1) IE912558A1 (no)
IL (1) IL98845A0 (no)
NO (1) NO912825L (no)
PT (1) PT98380A (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047042A1 (en) * 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
CA2047078A1 (en) * 1990-07-19 1992-01-20 Steven S. Bondy Cyclic hiv principal neutralizing determinant peptides
CA2047033A1 (en) * 1990-07-19 1992-01-20 Elizabeth E. Sugg Cyclic hiv principal neutralizing determinant peptides
CA2058876A1 (en) * 1991-12-19 1993-06-20 Maria A. Bednarek Cyclic hiv principal neutralizing determinant peptides
GB2271995A (en) * 1992-10-15 1994-05-04 Merck & Co Inc HIV peptide conjugated via anionic spacer to protein
GB2282380A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugate of epitopes of HIV with a protein complex from Neisseria
GB2282378A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugates of epitopes of HIV with a protein complex from Neisseria
US6664367B1 (en) * 1994-07-21 2003-12-16 Biosynthema, Inc. Stable analogs of bioactive peptides containing disulfide linkages
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
WO2000003737A2 (en) * 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble drugs and methods for their production
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
DE19936715A1 (de) * 1999-08-06 2001-02-15 Ticona Gmbh Emissionsarme eingefärbte Polyoxymethylen-Formmassen
CA2409287A1 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
EP1178317B1 (en) 2000-07-24 2004-11-10 Health Research, Inc. Method for detection of prostate specific membrane antigen in serum
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
EP1569955A2 (en) * 2002-12-03 2005-09-07 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
WO2004073659A2 (en) * 2003-02-14 2004-09-02 Merck & Co., Inc. HIV gp120 MIMOTOPE ANTIGEN
BRPI0407877A (pt) * 2003-03-07 2006-03-01 Merck & Co Inc conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
US20090104220A1 (en) * 2003-12-18 2009-04-23 Elisabetta Bianchi Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity
WO2006124712A2 (en) * 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
KR102289985B1 (ko) 2014-12-08 2021-08-17 삼성디스플레이 주식회사 표시 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4762913A (en) * 1973-05-07 1988-08-09 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
JPH01500432A (ja) * 1986-07-21 1989-02-16 サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ Ａｉｄｓおよびａｒｃのウィルス原因物質に対して免疫化するための組成物および方法
EP0255190A3 (en) * 1986-08-01 1990-08-29 Repligen Corporation Recombinant polypeptides and their uses, inclusing assay for aids virus
EP0289110A3 (en) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Conjugate malaria vaccine
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
IL87391A0 (en) * 1987-08-27 1989-01-31 Repligen Corp Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
DE3802060A1 (de) * 1988-01-25 1989-07-27 Boehringer Mannheim Gmbh Hapten-protein-konjugate und ihre verwendung
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0436634A1 (en) * 1988-10-03 1991-07-17 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
CA2047078A1 (en) * 1990-07-19 1992-01-20 Steven S. Bondy Cyclic hiv principal neutralizing determinant peptides
DE4033714C3 (de) * 1990-10-24 1995-09-07 Brahms Diagnostica Gmbh Neues Hapten-Analytikum basierend auf dem Prinzip einer Antigen-Antikörper-Reaktion

Also Published As

Publication number Publication date
EP0467700A2 (en) 1992-01-22
US5606030A (en) 1997-02-25
IL98845A0 (en) 1992-07-15
IE912558A1 (en) 1992-01-29
NO912825D0 (no) 1991-07-18
AU8113591A (en) 1992-01-23
EP0467700A3 (en) 1993-03-10
FI913476A0 (fi) 1991-07-18
CA2047073A1 (en) 1992-01-20
FI913476L (fi) 1992-01-20
FI913476A7 (fi) 1992-01-20
JPH0625300A (ja) 1994-02-01
PT98380A (pt) 1992-05-29
KR920002633A (ko) 1992-02-28
JPH07113038B2 (ja) 1995-12-06

Similar Documents

Publication Publication Date Title
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
NO884795D0 (no) Rekombinant, humant immunoglobulin og fremgangsmaate for fremstilling av dette.
DK93388D0 (da) Lav-virusvarianter, dna- og proteinbestanddele deraf og anvendelse deraf, saerlig til diagnostiske formaal og til fremstilling af immunogene praeparater
NO900577D0 (no) Cyklosporinholdige preparater og fremgangsmaate for deres fremstilling.
NL8003762A (nl) Nieuwe tetra- of pentapeptiden, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze peptiden bevatten.
NL300249I2 (en) Cephalosporins and homologues, preparations and pharmaceutical preparations.
NO871025D0 (no) Polypeptid, dna og fremgangsmaate for fremstilling derav.
NO874530L (no) Fremgangsmaate for fremstilling av nor-statin- eller nor-cyklostatin-polypeptider.
NO883834D0 (no) Fremgangsmaate for fremstilling av nye hiv-proteiner og peptider.
DK196687A (da) Kombineret vaccine, samt fremgangsmaade til fremstilling deraf
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO903347D0 (no) Fremgangsmaate for fremstilling av 14,17alfa-ethano- og ethanooestratriener.
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
EP0311228A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
NO911543D0 (no) Katalysatorsystem og fremgangsmaate for fremstilling av 1,2-diklorethan.
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
NO874106D0 (no) Anioniske kopolymerer, samt fremgangsmaate for fremstilling av slike, og anvendelse av kopolymerene.
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
FI873483A7 (fi) Oksiraanipseudo-oligosakkarideja, menetelmä niiden valmistamiseksi, niiden käyttö ja farmaseuttisia valmisteita.
ZA915626B (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties
AU1814792A (en) Immunogenic peptides or polypeptides of the bvd virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof
NO893796L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO912192D0 (no) Rekombinante dna og fremgangsmaate for fremstilling av chimere antistoffer.